Lambert Marion, Gannagé Monique, Karras Alexandre, Abel Michal, Legendre Christophe, Kerob Delphine, Agbalika Felix, Girard Pierre-Marie, Lebbe Celeste, Caillat-Zucman Sophie
INSERM U561, Hôpital St-Vincent de Paul, 75014 Paris, France.
Blood. 2006 Dec 1;108(12):3871-80. doi: 10.1182/blood-2006-03-014225. Epub 2006 Aug 22.
It is unclear how the immune response controls human herpesvirus 8 (HHV8; also known as Kaposi sarcoma-associated herpesvirus [KSHV]) replication and thereby prevents Kaposi sarcoma (KS). We compared CD8 T-cell responses to HHV8 latent (K12) and lytic (glycoprotein B, ORF6, ORF61, and ORF65) antigens in patients who spontaneously controlled the infection and in patients with posttransplantation, AIDS-related, or classical KS. We found that anti-HHV8 responses were frequent, diverse, and strongly differentiated toward an effector phenotype in patients who controlled the infection. Conversely, HHV8-specific CD8 cells were very rare in patients who progressed to KS, and were not recruited to the tumoral tissue, as visualized by in situ tetramer staining of KS biopsies. Last, HHV8-specific CD8 T cells were observed in a seronegative recipient of an HHV8infected graft who remained persistently aviremic and antibody negative, suggesting that specific cytotoxic T lymphocytes (CTLs) may provide protection from persistent HHV8 infection. These results support the crucial role of cellular immune responses in controlling HHV8 replication, in preventing malignancies in latently infected subjects, and in conferring genuine resistance to persistent infection. They may also have important implications for the design of prophylactic and therapeutic HHV8 vaccines, and for adoptive immunotherapy of KS.
目前尚不清楚免疫反应如何控制人类疱疹病毒8型(HHV8;也称为卡波西肉瘤相关疱疹病毒[KSHV])的复制,从而预防卡波西肉瘤(KS)。我们比较了自发控制感染的患者以及移植后、艾滋病相关或经典型KS患者中CD8 T细胞对HHV8潜伏(K12)和裂解(糖蛋白B、ORF6、ORF61和ORF65)抗原的反应。我们发现,在控制感染的患者中,抗HHV8反应频繁、多样且强烈分化为效应细胞表型。相反,在进展为KS的患者中,HHV8特异性CD8细胞非常罕见,并且未被募集到肿瘤组织中,这通过KS活检组织的原位四聚体染色得以证实。最后,在接受HHV8感染移植物的血清阴性受者中观察到HHV8特异性CD8 T细胞,该受者持续无病毒血症且抗体阴性,这表明特异性细胞毒性T淋巴细胞(CTL)可能提供针对持续性HHV8感染的保护。这些结果支持了细胞免疫反应在控制HHV8复制、预防潜伏感染个体发生恶性肿瘤以及赋予对持续性感染的真正抵抗力方面的关键作用。它们可能也对HHV8预防性和治疗性疫苗的设计以及KS的过继免疫治疗具有重要意义。